BioSpace News Archive

Insulet Corporation announced the following appointments to the Company’s Board of Directors, effective January 18.

Acadia Pharmaceuticals Inc. is saddened to announce the passing of its former President, Srdjan Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness.

Kane Biotech Inc. announces that on February 20, 2024, the Company will hold a special meeting of its shareholders to consider the election of Dr. Robert Huizinga as an additional director of the Company.

GH Research PLC (Nasdaq: GHRS) today announced that it recently received a communication from the European Patent Office (EPO) that it has been granted a patent with claims directed to mebufotenin (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder (MDD) and treatment-resistant forms of MDD, such as treatment-resistant depression (TRD).

Bausch Health Companies Inc. and Solta Medical, a global leader in the medical aesthetics market, announced the approval of Thermage® FLX and the TR-4 Return Pad by China’s National Medical Products Administration.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL).

Myriad Genetics, Inc. announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor® (rexlemestrocel-L) a Rare Pediatric Disease (RPD) Designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced that the newly established Queensland Spatial Biology Centre, located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial biology platform as the core technology to revolutionize the way cancer and other debilitating diseases are diagnosed and treated.

Enigma Biomedical Group - USA (EBG-USA) today announced it has signed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie’s next-generation F18 PET imaging biomarkers to assess the presence of four-repeat (4R) tau protein in patients with suspected neurodegenerative disease.